In the wake of the passing of the 21st Century Cures Act last December, Food and Drug Administration (FDA) released several guidance documents aimed at providing manufacturers with expanded regulatory latitude for product-related communications and promotion. With mounting pressure from industry and advocacy to expedite market approval of new therapies, FDA’s efforts signals a leaning to release or minimize regulatory restrictions that in the past have restricted the ability of manufacturers to promote products.
After attempting to repeal the Affordable Care Act more than 60 times in the last 5 years, Republican lawmakers have a chance to dismantle the health care law as early as the next few weeks. Last month, the House and Senate passed a bill that could be used to cut funds to key parts of the legislation. However, Republicans remain divided over how fast to move on repealing Obamacare without having a viable replacement plan ready to implement.